Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Understanding the Burden of Nonalcoholic Fatty Liver Disease: Time for Action
Zobair M. Younossi, Linda Henry
Diabetes Spectrum (2024) Vol. 37, Iss. 1, pp. 9-19
Open Access | Times Cited: 17

Showing 17 citing articles:

Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
Diana Barb, Srilaxmi Kalavalapalli, Eddison Godinez Leiva, et al.
Journal of Hepatology (2025)
Open Access | Times Cited: 4
The growing range of complications of diabetes mellitus
Peter Shane Hamblin, Anthony Russell, Stella Talic, et al.
Trends in Endocrinology and Metabolism (2025)
Closed Access | Times Cited: 1
Nonalcoholic Fatty Liver Disease in Diabetes: A Call to Action
Kenneth Cusi
Diabetes Spectrum (2024) Vol. 37, Iss. 1, pp. 5-7
Open Access | Times Cited: 6
Association between cardiovascular health and metabolic dysfunction-associated steatotic liver disease: a nationwide cross-sectional study
Lian-Zhen Huang, Zi-Wei Ni, Wei-Feng Huang, et al.
Journal of Health Population and Nutrition (2025) Vol. 44, Iss. 1
Open Access
“Evaluation of Curcuma zedoaria Rosc. in the management of non-alcoholic fatty liver Disease: A Randomized, single blind, controlled trial”
Aaqib Ashraf, Shameem Ahmad Rather, Mahvish Mehraj
Arab Journal of Gastroenterology (2025)
Closed Access
Reactive Dicarbonyl Scavenging with 2-Hydroxybenzylamine Improves MASH
Joyce Cheung‐Flynn, John A. Rathmacher, Lisa M. Pitchford, et al.
Nutrients (2025) Vol. 17, Iss. 4, pp. 610-610
Open Access
Glucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss
Lalitha Sundararaman, Divakara Gouda, Anil Kumar, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 6, pp. 1978-1978
Open Access
Making Sense of the Nonalcoholic Fatty Liver Disease Clinical Practice Guidelines: What Clinicians Need to Know
Kenneth Cusi, Jeff Budd, Eric L. Johnson, et al.
Diabetes Spectrum (2024) Vol. 37, Iss. 1, pp. 29-38
Open Access | Times Cited: 4
Modified FIB-4 Index in Type 2 Diabetes Mellitus with Steatosis: A Non-Linear Predictive Model for Advanced Hepatic Fibrosis
Jonghyun Kim, Takanori Ito, Taeang Arai, et al.
Diagnostics (2024) Vol. 14, Iss. 22, pp. 2500-2500
Open Access | Times Cited: 1
Detecting altered hepatic lipid oxidation by MRI in an animal model of MASLD
Marc McLeod, Mario C. Chang, Anna Rushin, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 9, pp. 101714-101714
Open Access
BRUCE liver-deficiency potentiates MASLD/MASH in PTEN liver-deficient background by impairment of mitochondrial metabolism in hepatocytes and activation of STAT3 signaling in hepatic stellate cells
Lixiao Che, C Stevenson, David R. Plas, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Closed Access
The nonlinear connection between relative fat mass and non-alcoholic fatty liver disease in the Japanese population: an analysis based on data from a cross-sectional study
Changchun Cao, Meiling Huang, Yong Han, et al.
Diabetology & Metabolic Syndrome (2024) Vol. 16, Iss. 1
Open Access
OTUD1 regulates cytokine expression and related pathways in goose fatty liver by promoting deubiquitination of its target proteins
Xiaoyi Zhou, Ya Xing, Yuqing Wang, et al.
Poultry Science (2024) Vol. 103, Iss. 12, pp. 104382-104382
Open Access
Metformin: Beyond Type 2 Diabetes Mellitus
Rahnuma Ahmad, Mainul Haque
Cureus (2024)
Open Access
Exploring the Epidemiology and Awareness of Metabolic dysfunction-associated steatotic liver disease (MASLD) Among Health Sciences Students in an academic health care institute in India.
S Umasankari, S. Aishwarya, S.K. Aishwarya, et al.
Metabolism Open (2024) Vol. 24, pp. 100325-100325
Open Access
Progress in pediatric cardiology VSI: Cardiovascular disease in pediatrics lipoprotein(a) in atherosclerotic cardiovascular disease, type 2 diabetes, and liver disease
Kent A. Williams, Molly Augustine, Eru Sujakhu, et al.
Progress in Pediatric Cardiology (2024), pp. 101775-101775
Open Access
The Pan-PPAR Agonist Lanifibranor Reverses Metabolic Dysfunction in People with Type 2 Diabetes and MASLD: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
Diana Barb, Srilaxmi Kalavalapalli, Eddison Godinez Leiva, et al.
(2024)
Closed Access
Inhibition of the miR-1914-5p increases the oxidative metabolism in cellular model of steatosis by modulating the Sirt1-PGC-1α pathway and systemic cellular activity
Thais Porto-Barbosa, Letícia Ferreira Ramos, Camila Cristiane Pansa, et al.
PLoS ONE (2024) Vol. 19, Iss. 11, pp. e0313185-e0313185
Open Access
Page 1

Scroll to top